The Zhitong Finance App learned that on August 10, Bristol-Myers Squibb (BMY.US) announced a collaboration with GentiBio to develop regulatory T cell (Treg) therapy for inflammatory bowel disease (IBD).
Over many years of collaboration, GenTiBio will use its modular engineering Treg platform and scalable manufacturing processes to produce stable and disease-specific engineered Treg for multiple targets. Bristol-Myers Squibb will have the right to develop and advance three of these projects into clinical trials.
Bristol-Myers Squibb prepaid GenTiBio an undisclosed amount of cash. Additionally, GenTiBio is eligible for development and sales milestone payments and royalties of up to $1.9 billion.